Skip to content



Page 2 of 35

  1. Content type: Case report

    Pembrolizumab, an anti-programmed cell death-1 protein monoclonal antibody, is effective for patients with advanced non-small-cell lung cancer. However, immune checkpoint inhibitors such as pembrolizumab induc...

    Authors: Teppei Sugano, Masahiro Seike, Yoko Funasaka, Mai Yoshida, Ryoko Takayama, Ken Okamura, Asuka Nakanishi, Toru Tanaka, Susumu Takeuchi, Rintaro Noro, Yuji Minegishi, Kaoru Kubota, Hidehisa Saeki and Akihiko Gemma

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:59

    Published on:

  2. Content type: Research article

    Systemic and local immune suppression plays a significant role in glioma progression. Glioma microenvironment contains both brain-resident microglial cells (MG) and bone marrow-derived macrophages (BMDM), but ...

    Authors: Laura Pinton, Elena Masetto, Marina Vettore, Samantha Solito, Sara Magri, Marta D’Andolfi, Paola Del Bianco, Giovanna Lollo, Jean-Pierre Benoit, Hideho Okada, Aaron Diaz, Alessandro Della Puppa and Susanna Mandruzzato

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:58

    Published on:

  3. Content type: Research article

    Recent evidence suggested a potential correlation between overweight and the efficacy of immune checkpoint inhibitors (ICIs) in cancer patients.

    Authors: Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti, Katia Cannita, Daniele Santini, Fabiana Perrone, Raffaele Giusti, Marcello Tiseo, Maria Michiara, Pietro Di Marino, Nicola Tinari, Michele De Tursi, Federica Zoratto, Enzo Veltri, Riccardo Marconcini, Francesco Malorgio…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:57

    Published on:

  4. Content type: Correction

    Following publication of the original article [1], the authors reported an error in the typesetting of their article. The first section of the main text was mistakenly included in the abstract.

    Authors: Shanta Bantia and Nirmal Choradia

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:56

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2018 6:143

  5. Content type: Research article

    Immunogenic radiotherapy (RT) can act synergistically with immune checkpoint blockers (ICBs). However, alternatives are needed for non-responding patients and those with pre-existing or ICB-induced autoimmune ...

    Authors: Hua Jing, Michael Hettich, Simone Gaedicke, Elke Firat, Mark Bartholomä and Gabriele Niedermann

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:55

    Published on:

  6. Content type: Research article

    Mast cells are prominent components of solid tumors and exhibit distinct phenotypes in different tumor microenvironments. However, the nature, regulation, function, and clinical relevance of mast cells in huma...

    Authors: Yipin Lv, Yongliang Zhao, Xianhua Wang, Na Chen, Fangyuan Mao, Yongsheng Teng, Tingting Wang, Liusheng Peng, Jinyu Zhang, Ping Cheng, Yugang Liu, Hui Kong, Weisan Chen, Chuanjie Hao, Bin Han, Qiang Ma…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:54

    Published on:

  7. Content type: Research article

    Influenza vaccination (FV) is recommended for patients with cancer. Recent data suggested that the administration of the FV was associated with an increase in immune-related adverse events (irAEs) among patien...

    Authors: Magid Awadalla, Doll Lauren Alexandra Golden, Syed S. Mahmood, Raza M. Alvi, Nathaniel D. Mercaldo, Malek Z. O. Hassan, Dahlia Banerji, Adam Rokicki, Connor Mulligan, Sean P. T. Murphy, Maeve Jones-O’Connor, Justine V. Cohen, Lucie M. Heinzerling, Merna Armanious, Ryan J. Sullivan, Rongras Damrongwatanasuk…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:53

    Published on:

  8. Content type: Case report

    Treatment with a combination of PD-1 and CTLA-4 targeted checkpoint inhibition has improved outcome of melanoma patients and led to durable remissions but is also associated with significant toxicities. Endocr...

    Authors: Beckey Trinh, Guacimara Ortega Sanchez, Petra Herzig and Heinz Läubli

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:52

    Published on:

  9. Content type: Case report

    The aggressive form of Mantle cell non-hodgkin B cell lymphoma (MCL) has a dismal prognosis. Dual targeting BTK and BCL2 with ibrutinib and venetoclax has improved outcomes in MCL patients who were predicted n...

    Authors: Tongjuan Li, Yuanyuan Zhang, Dan Peng, Xia Mao, Xiaoxi Zhou and Jianfeng Zhou

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:51

    Published on:

  10. Content type: Research article

    Long-term survival of stage IV melanoma patients has improved significantly with the development of immune checkpoint inhibitors (CIs). Reliable biomarkers to predict response and clinical outcome are needed.

    Authors: Mirjam Fässler, Stefan Diem, Joanna Mangana, Omar Hasan Ali, Fiamma Berner, David Bomze, Sandra Ring, Rebekka Niederer, Cristina del Carmen Gil Cruz, Christian Ivan Pérez Shibayama, Michal Krolik, Marco Siano, Markus Joerger, Mike Recher, Lorenz Risch, Sabine Güsewell…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:50

    Published on:

  11. Content type: Research article

    Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies are needed. High dose interleukin-2 (HD IL-2) can...

    Authors: Elizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Brendan D. Curti, Sapna P. Patel, Shernan G. Holtan, Gerald P. Miletello, Mayer N. Fishman, Rene Gonzalez, Joseph I. Clark, John M. Richart, Christopher D. Lao, Scott S. Tykodi, Ann W. Silk and David F. McDermott

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:49

    Published on:

  12. Content type: Research article

    The development of memory responses is an evolutionary function of the adaptive immune system. We propose that for the immune system to populate the memory compartment with the best-suited CD8 T cells it utili...

    Authors: Cynthia Perez, Kushal Prajapati, Brianna Burke, Lourdes Plaza-Rojas, Nancy J. Zeleznik-Le and Jose A. Guevara-Patino

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:48

    Published on:

  13. Content type: Case report

    Immune checkpoint inhibitors (ICPIs), used to treat different advanced malignancies, are associated with a wide range of immune-related adverse reactions (irAEs) that deserve close monitoring of patients. Gast...

    Authors: Hao Chi Zhang, Wenyi Luo and Yinghong Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:47

    Published on:

  14. Content type: Correction

    After publication of this supplement [1, 2], it was brought to our attention that due to an error authors were missing in the following abstracts. This has now been included in this correction.

    Authors: Sneha Berry, Nicolas Giraldo, Peter Nguyen, Benjamin Green, Haiying Xu, Aleksandra Ogurtsova, Abha Soni, Farah Succaria, Daphne Wang, Charles Roberts, Julie Stein, Elizabeth Engle, Drew Pardoll, Robert Anders, Tricia Cottrell, Janis M. Taube…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:46

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2018 6:115

    The original article was published in Journal for ImmunoTherapy of Cancer 2018 6:114

  15. Content type: Research article

    The thymic stromal lymphopoietin (TSLP), a key cytokine for development of Th2 immunity, is produced by cancer associated fibroblasts (CAFs) in pancreatic cancer where predominant tumor infiltrating Th2 over T...

    Authors: Emanuela Brunetto, Lucia De Monte, Gianpaolo Balzano, Barbara Camisa, Vincenzo Laino, Michela Riba, Silvia Heltai, Marco Bianchi, Claudio Bordignon, Massimo Falconi, Attilio Bondanza, Claudio Doglioni and Maria Pia Protti

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:45

    Published on:

  16. Content type: Research article

    Salmonella have potential as anticancer therapeutic because of their innate tumor specificity. In clinical studies, this specificity has been hampered by heterogeneous responses. Understanding the mechanisms that...

    Authors: Vishnu Raman, Nele Van Dessel, Owen M. O’Connor and Neil S. Forbes

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:44

    Published on:

  17. Content type: Research article

    Cervical cancer (CxCa) is mainly a locally invading disease that metastasizes to loco-regional lymph node basins before involving distant organs in more advanced stages. Local immune potentiation of tumor-drai...

    Authors: A. M. Heeren, J. Rotman, A. G. M. Stam, N. Pocorni, A. A. Gassama, S. Samuels, M. C. G. Bleeker, C. H. Mom, H. J. M. A. A. Zijlmans, G. G. Kenter, E. S. Jordanova and T. D. de Gruijl

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:43

    Published on:

  18. Content type: Research article

    Chemotherapy combined with immunotherapy becomes the main trend in lung cancer intervention; however, how chemotherapy promotes the immune function remains elusive. Therefore, we sought to determine how chemot...

    Authors: Qun Gao, Shumin Wang, Xinfeng Chen, Shaoyan Cheng, Zhen Zhang, Feng Li, Lan Huang, Yang Yang, Bin Zhou, Dongli Yue, Dan Wang, Ling Cao, Nomathamsanqa Resegofetse Maimela, Bin Zhang, Jane Yu, Liping Wang…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:42

    Published on:

  19. Content type: Case report

    Alongside its clinical success, checkpoint blockade has also given rise to a set of immune-related adverse events (irAEs). In addition to causing considerable morbidity and even mortality, irAEs may limit the ...

    Authors: Elisa Bello, Justine V. Cohen, Mari Mino-Kenudson and Michael Dougan

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:41

    Published on:

  20. Content type: Case report

    Several predictive biomarkers are currently approved or are under investigation for the selection of patients for checkpoint blockade. Tumor PD-L1 expression is used for stratification of non-small cell lung (...

    Authors: Kellie N. Smith, Nicolas J. Llosa, Tricia R. Cottrell, Nicholas Siegel, Hongni Fan, Prerna Suri, Hok Yee Chan, Haidan Guo, Teniola Oke, Anas H. Awan, Franco Verde, Ludmila Danilova, Valsamo Anagnostou, Ada J. Tam, Brandon S. Luber, Bjarne R. Bartlett…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:40

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:63

  21. Content type: Research article

    In oncology clinical development, objective response rate, disease control rate and early tumor size changes are commonly used as efficacy metrics for early decision-making. However, for immunotherapy trials, ...

    Authors: Meihua Wang, Cong Chen, Thomas Jemielita, James Anderson, Xiaoyun (Nicole) Li, Chen Hu, S. Peter Kang, Nageatte Ibrahim and Scot Ebbinghaus

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:39

    Published on:

  22. Content type: Research article

    Preclinical studies demonstrate synergism between cancer immunotherapy and local radiation, enhancing anti-tumor effects and promoting immune responses. BI1361849 (CV9202) is an active cancer immunotherapeutic...

    Authors: Alexandros Papachristofilou, Madeleine M. Hipp, Ute Klinkhardt, Martin Früh, Martin Sebastian, Christian Weiss, Miklos Pless, Richard Cathomas, Wolfgang Hilbe, Georg Pall, Thomas Wehler, Jürgen Alt, Helge Bischoff, Michael Geißler, Frank Griesinger, Karl-Josef Kallen…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:38

    Published on:

  23. Content type: Research article

    The success of agents that reverse T-cell inhibitory signals, such as anti-PD-1/PD-L1 therapies, has reinvigorated cancer immunotherapy research. However, since only a minority of patients respond to single-ag...

    Authors: A. Capasso, J. Lang, T. M. Pitts, K. R. Jordan, C. H. Lieu, S. L. Davis, J. R. Diamond, S. Kopetz, J. Barbee, J. Peterson, B. M. Freed, B. W. Yacob, S. M. Bagby, W. A. Messersmith, J. E. Slansky, R. Pelanda…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:37

    Published on:

  24. Content type: Case report

    Cholangiocarcinoma (CCA) is a highly aggressive and fatal tumor. CCA occurs in the epithelial cells of bile ducts. Due to increasing incidences, CCA accounts for 3% of all gastrointestinal malignancies. In add...

    Authors: Mohammed Alnaggar, Yan Xu, Jingxia Li, Junyi He, Jibing Chen, Man Li, Qingling Wu, Li Lin, Yingqing Liang, Xiaohua Wang, Jiawei Li, Yi Hu, Yan Chen, Kecheng Xu, Yangzhe Wu and Zhinan Yin

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:36

    Published on:

  25. Content type: Research article

    The aim of this study is to evaluate the prognostic impact of myeloid-derived suppressor cells (MDSCs) in multiple myeloma (MM) in the context of autologous stem cell transplantation (ASCT).

    Authors: Sung-Eun Lee, Ji-Young Lim, Tae Woo Kim, Da-Bin Ryu, Sung Soo Park, Young-Woo Jeon, Jae-Ho Yoon, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee and Chang-Ki Min

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:35

    Published on:

  26. Content type: Research article

    The role of programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) in triple negative breast cancer (TNBC) remains to be fully understood. In this study, we investigated the role of PD-1...

    Authors: Joe Yeong, Jeffrey Chun Tatt Lim, Bernett Lee, Huihua Li, Clara Chong Hui Ong, Aye Aye Thike, Wei Hseun Yeap, Yi Yang, Ansel Yi Herh Lim, Timothy Kwang Yong Tay, Jin Liu, Siew-Cheng Wong, Jinmiao Chen, Elaine Hsuen Lim, Jabed Iqbal, Rebecca Dent…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:34

    Published on:

  27. Content type: Research article

    Therapies targeting anti-tumor T-cell responses have proven successful in the treatment of a variety of malignancies. However, as most patients still fail to respond, approaches to augment immunotherapeutic ef...

    Authors: Andressa S. Laino, B. C. Betts, A. Veerapathran, I. Dolgalev, A. Sarnaik, S. N. Quayle, S. S. Jones, J. S. Weber and David M. Woods

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:33

    Published on:

  28. Content type: Research article

    Tumor orchestrated metabolic changes in the microenvironment limit generation of anti-tumor immune responses. Availability of arginine, a semi-essential amino acid, is critical for lymphocyte proliferation and...

    Authors: Juan J. Miret, Paul Kirschmeier, Shohei Koyama, Mingrui Zhu, Yvonne Y. Li, Yujiro Naito, Min Wu, Venkat S. Malladi, Wei Huang, William Walker, Sangeetha Palakurthi, Glenn Dranoff, Peter S. Hammerman, Chad V. Pecot, Kwok-Kin Wong and Esra A. Akbay

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:32

    Published on:

  29. Content type: Research article

    Immune checkpoint inhibitor (ICI)-induced pancreatic injury (ICIPI) is not well documented in the literature. We aimed to describe the clinical characteristics and outcomes of patients who developed ICIPI.

    Authors: Hamzah Abu-Sbeih, Tenglong Tang, Yang Lu, Selvi Thirumurthi, Mehmet Altan, Amir A. Jazaeri, Ramona Dadu, Emmanuel Coronel and Yinghong Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:31

    Published on:

  30. Content type: Research article

    We evaluated the antitumor activity and safety of avelumab, a human anti–PD-L1 IgG1 antibody, as first-line switch-maintenance (1 L-mn) or second-line (2 L) treatment in patients with advanced gastric/gastroes...

    Authors: Hyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, Sun Young Rha, Do-Youn Oh, Lucjan Wyrwicz, Yoon-Koo Kang, Keun-Wook Lee, Jeffrey R. Infante, Sung Sook Lee, Margaret Kemeny, Ulrich Keilholz, Bohuslav Melichar, Alain Mita, Ruth Plummer, Denis Smith…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:30

    Published on:

  31. Content type: Research article

    Triple-negative breast cancer (TNBC) treatment is currently restricted to chemotherapy. Hence, tumor-specific molecular targets and/or alternative therapeutic strategies for TNBC are urgently needed. Immunothe...

    Authors: Yahya Ashraf, Hanane Mansouri, Valérie Laurent-Matha, Lindsay B. Alcaraz, Pascal Roger, Séverine Guiu, Danielle Derocq, Gautier Robin, Henri-Alexandre Michaud, Helène Delpech, Marta Jarlier, Martine Pugnière, Bruno Robert, Anthony Puel, Lucie Martin, Flavie Landomiel…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:29

    Published on:

  32. Content type: Research article

    Tumor specific Th9 cells are potential effector cells for adoptive therapy of human cancers. TNF family members OX40L, TL1A and GITRL have been shown to promote the induction of Th9 cells and antitumor immunit...

    Authors: Yuxue Jiang, Jintong Chen, Enguang Bi, Yinghua Zhao, Tianxue Qin, Yiming Wang, Alison Wang, Sujun Gao, Qing Yi and Siqing Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:28

    Published on:

  33. Content type: Research article

    Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience with response prediction based on PD-L1 expressio...

    Authors: Sarabjot Pabla, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jacob Hagen, Vincent Giamo, Jonathan Andreas, Felicia L. Lenzo, Wang Yirong, Grace K. Dy, Edwin Yau, Amy Early, Hongbin Chen, Wiam Bshara…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:27

    Published on:

  34. Content type: Commentary

    Oncolytic viruses are an emerging class of immunotherapy agents for cancer treatment. In this issue of JITC, Machiels et al. reports early phase data from an oncolytic adenovirus given by intravenous (IV) admi...

    Authors: Howard L. Kaufman and Praveen K. Bommareddy

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:26

    Published on:

  35. Content type: Research article

    The capacity of cytomegalovirus (CMV) to elicit long-lasting strong T cell responses, and the ability to engineer the genome of this DNA virus positions CMV-based vaccine vectors highly suitable as a cancer va...

    Authors: Elham Beyranvand Nejad, Robert B. Ratts, Eleni Panagioti, Christine Meyer, Jennifer D. Oduro, Luka Cicin-Sain, Klaus Früh, Sjoerd H. van der Burg and Ramon Arens

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:25

    Published on:

  36. Content type: Research article

    Clinicopathological and molecular features of responders to nivolumab for advanced gastric cancer (AGC) are not well understood.

    Authors: Saori Mishima, Akihito Kawazoe, Yoshiaki Nakamura, Akinori Sasaki, Daisuke Kotani, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino, Takeshi Kuwata, Akihito Tsuji and Kohei Shitara

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:24

    Published on:

  37. Content type: Research article

    Immunotherapy has demonstrated remarkable success in treating different cancers. Nonetheless, a large number of patients do not respond, many respond without immediate changes detectable with conventional imag...

    Authors: Matthew Scarpelli, Christopher Zahm, Scott Perlman, Douglas G. McNeel, Robert Jeraj and Glenn Liu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:23

    Published on:

  38. Content type: Short report

    Chronic lymphocytic leukemia (CLL) is the most common type of leukemia and the anti-CD20 monoclonal antibody, rituximab, represents the therapeutic gold standard for more than 2 decades in this pathology, when...

    Authors: Cristina Bagacean, Adrian Tempescul, David Ternant, Anne Banet, Nathalie Douet-Guilbert, Anne Bordron, Boutahar Bendaoud, Hussam Saad, Mihnea Zdrenghea, Christian Berthou, Gilles Paintaud and Yves Renaudineau

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:22

    Published on:

  39. Content type: Research article

    Transient depletion of CD4+ T cells results in tumor suppression and survival benefit in murine models; however, the tumor progression and recurrence still occur over more long-term monitoring of mice. Thus, we e...

    Authors: Chang-Yu Chen, Satoshi Ueha, Yoshiro Ishiwata, Shoji Yokochi, De Yang, Joost J. Oppenheim, Haru Ogiwara, Shigeyuki Shichino, Shungo Deshimaru, Francis H. W. Shand, Shiro Shibayama and Kouji Matsushima

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:21

    Published on:

  40. Content type: Research article

    Enadenotucirev is a chimeric adenovirus with demonstrated preclinical tumor-selective cytotoxicity and a short half-life. Further clinical mechanism of action data showed that enadenotucirev can gain access to...

    Authors: Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey, Ignacio Duran, Luc Dirix, Karen Geboes, Christine Wilkinson-Blanc, Gillian Pover, Simon Alvis, Brian Champion, Kerry Fisher, Hilary McElwaine-Johnn, John Beadle and Emiliano Calvo

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:20

    Published on:

  41. Content type: Research article

    Oncolytic virus (OV)-based therapies have an emerging role in the treatment of solid tumors, involving both direct cell lysis and immunogenic cell death. Nonetheless, tumor-associated stroma limits the efficac...

    Authors: Jana de Sostoa, Carlos Alberto Fajardo, Rafael Moreno, Maria D. Ramos, Martí Farrera-Sal and Ramon Alemany

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:19

    Published on:

  42. Content type: Research article

    PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-...

    Authors: Jeffrey M. Conroy, Sarabjot Pabla, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo, Yirong Wang, Felicia L. Lenzo, Wiam Bshara, Maya Khalil, Grace K. Dy, Katherine G. Madden, Keisuke Shirai, Konstantin Dragnev…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:18

    Published on:

  43. Content type: Research article

    The advents of novel immunotherapies have revolutionized the treatment of cancer. Adoptive cellular therapies using chimeric antigen receptor T (CAR-T) cells have achieved remarkable clinical responses in B ce...

    Authors: Junlin Yao, Dalam Ly, Dzana Dervovic, Linan Fang, Jong Bok Lee, Hyeonjeong Kang, Yu-Hui Wang, Nhu-An Pham, Hongming Pan, Ming-Sound Tsao and Li Zhang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:17

    Published on:

  44. Content type: Research article

    Increasing evidence suggests that antibody-drug conjugates (ADCs) can enhance anti-tumor immunity and improve clinical outcome. Here, we elucidate the therapeutic efficacy and immune-mediated mechanisms of a n...

    Authors: Lucia D’Amico, Ulrike Menzel, Michael Prummer, Philipp Müller, Mélanie Buchi, Abhishek Kashyap, Ulrike Haessler, Alexander Yermanos, Rémy Gébleux, Manfred Briendl, Tamara Hell, Fabian I. Wolter, Roger R. Beerli, Iva Truxova, Špíšek Radek, Tatjana Vlajnic…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:16

    Published on:

  45. Content type: Research article

    Clinical benefit from checkpoint inhibitors has been associated in a tumor-agnostic manner with two main tumor traits. The first is tumor antigenicity, which is typically measured by tumor mutation burden, mic...

    Authors: Patrick Danaher, Sarah Warren, SuFey Ong, Nathan Elliott, Alessandra Cesano and Sean Ferree

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:15

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:76

  46. Content type: Research article

    Regulatory T cells (Tregs) may comprise different subsets allowing them to efficiently suppress different types of effector T cells. In this study, we show that high numbers of both conventional and Tbet co-ex...

    Authors: S. J. Santegoets, C. L. Duurland, E. S. Jordanova, J. J. van Ham, I. Ehsan, S. L. van Egmond, M. J. P. Welters and S. H. van der Burg

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:14

    Published on:

  47. Content type: Research article

    The tumor microenvironment (TME) is a complex mixture of tumor epithelium, stroma and immune cells, and the immune component of the TME is highly prognostic for tumor progression and patient outcome. In lung c...

    Authors: Katey S. S. Enfield, Spencer D. Martin, Erin A. Marshall, Sonia H. Y. Kung, Paul Gallagher, Katy Milne, Zhaoyang Chen, Brad H. Nelson, Stephen Lam, John C. English, Calum E. MacAulay, Wan L. Lam and Martial Guillaud

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:13

    Published on:

  48. Content type: Research article

    We report phase 1b data from patients enrolled in the JAVELIN Solid Tumor clinical trial (NCT01772004) with unresectable stage IIIC or IV melanoma that had progressed after ≥1 line of therapy for metastatic di...

    Authors: Ulrich Keilholz, Janice M. Mehnert, Sebastian Bauer, Hugues Bourgeois, Manish R. Patel, Donald Gravenor, John J. Nemunaitis, Matthew H. Taylor, Lucjan Wyrwicz, Keun-Wook Lee, Vijay Kasturi, Kevin Chin, Anja von Heydebreck and James L. Gulley

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:12

    Published on:

  49. Content type: Short report

    Expression of PDL1 on the surface of tumor cells can blunt the efficacy of many cancer immunotherapies. For example, our lab has previously shown that tumors derived from malignant cells incapable of expressin...

    Authors: Mee Y. Bartee, Parker C. Dryja and Eric Bartee

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:11

    Published on:

  50. Content type: Research article

    Chemoradiotherapy (CRT) remains one of the most common cancer treatment modalities, and recent data suggest that CRT is maximally effective when there is generation of an anti-tumoral immune response. However,...

    Authors: Aurelie Hanoteau, Jared M. Newton, Rosemarie Krupar, Chen Huang, Hsuan-Chen Liu, Angelina Gaspero, Robyn D. Gartrell, Yvonne M. Saenger, Thomas D. Hart, Saskia J. Santegoets, Damya Laoui, Chad Spanos, Falguni Parikh, Padmini Jayaraman, Bing Zhang, Sjoerd H. Van der Burg…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:10

    Published on:

Annual Journal Metrics